Close Menu

NEW YORK – NeoGenomics said late on Wednesday that it has priced a public offering of its common stock and convertible senior notes for a total of $500 million in gross proceeds.

The Fort Myers, Florida-based firm is offering 4,081,632 shares of its common stock at $49.00 per share. It also is offering $300 million aggregate principal amount of its .25 percent convertible senior notes due January 2028 for gross proceeds of $300 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Researchers are developing a breath test to determine how severe patients' methylmalonic acidemia disease is, FierceBiotech reports.

NPR reports that vaccine developers are working on SARS-CoV-2 vaccines that are easier to store or administer than the current crop.

Reuters reports that France is to recommend that people under 55 who received one dose of AstraZeneca's SARS-CoV-2 vaccine receive a different vaccine for their second dose.